ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015
Dopaminergic system dysfunction in recreational dexamphetamine users.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [European journal of nuclear medicine and molecular imaging · 2023Pooled it
- Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine: A Systematic Review and Meta-analysis.JAMA psychiatry · 2017Pooled it
- Acute drug effects differentially predict desire to take dextroamphetamine again for work and recreation.Psychopharmacology · 2021Trial
- Age-Dependent Effects of Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.JAMA psychiatry · 2016Trial
- Neuroimaging of the monoaminergic system in Parkinson's disease: A narrative review.Neuroimage. Reports · 2026Review
- Pharmacotherapies for stimulant use disorder and co-occurring attention deficit hyperactivity disorder: protocol for a systematic review and a meta-analysis.Frontiers in psychiatry · 2025Article
- The influence of drug class on reward in substance use disorders.Pharmacology, biochemistry, and behavior · 2024Review
- What Causes Premature Coronary Artery Disease?Current atherosclerosis reports · 2024Review
- Thymoquinone: FromIranian journal of basic medical sciences · 2020Review
- Striatal Dopamine Release in Response to Morphine: A [Biological psychiatry · 2019Article
- Long-term effects of stimulant exposure on cerebral blood flow response to methylphenidate and behavior in attention-deficit hyperactivity disorder.Brain imaging and behavior · 2018Article
- Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate.PloS one · 2017Article
- Heightened Dopaminergic Response to Amphetamine at the DNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Article
- Effects of dexamphetamine-induced dopamine release on resting-state network connectivity in recreational amphetamine users and healthy controls.Brain imaging and behavior · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dexamphetamine (dAMPH) is a stimulant drug that is widely used recreationally as well as for the treatment of attention-deficit hyperactivity disorder (ADHD). Although animal studies have shown neurotoxic effects of dAMPH on the dopaminergic system, little is known about such effects on the human brain. Here, we studied the dopaminergic system at multiple physiological levels in recreational dAMPH users and age, gender, and IQ-matched dAMPH-naïve healthy controls. We assessed baseline D2/3 receptor availability, in addition to changes in dopamine (DA) release using single-photon emission computed tomography and DA functionality using pharmacological magnetic resonance imaging, following a dAMPH challenge. Also, the subjective responses to the challenge were determined. dAMPH users displayed significantly lower striatal DA D2/3 receptor binding compared with healthy controls. In dAMPH users, we further observed a blunted DA release and DA functionality to an acute dAMPH challenge, as well as a blunted subjective response. Finally, the lower D2/3 availability, the more pleasant the dAMPH administration was experienced by control subjects, but not by dAMPH users. Thus, in agreement with preclinical studies, we show that the recreational use of dAMPH in human subjects is associated with dopaminergic system dysfunction. These findings warrant further (longitudinal) investigations and call for caution when using this drug recreationally and for ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.